{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:09:49Z","timestamp":1788217789796,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jcyt.2026.102067","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:17:29Z","timestamp":1769185049000},"page":"102067","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of salvage allogeneic transplantation for relapsed or refractory AML in nonremission: insights from real-world practice"],"prefix":"10.1016","volume":"28","author":[{"given":"Seungah","family":"Cha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Yeop","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7829-397X","authenticated-orcid":false,"given":"Junshik","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja Min","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102067_bib0001","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1158\/1078-0432.CCR-22-0809","article-title":"Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed\/refractory acute myeloid leukemia: an ALWP\/EBMT analysis","volume":"28","author":"Nagler","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102067_bib0002","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s44313-024-00041-7","article-title":"How to improve AML outcomes?","volume":"59","author":"Tan","year":"2024","journal-title":"Blood Res"},{"key":"10.1016\/j.jcyt.2026.102067_bib0003","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcyt.2026.102067_bib0004","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102067_bib0005","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.2021014586","article-title":"Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102067_bib0006","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of relapsed acute myeloid leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jcyt.2026.102067_bib0007","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1159\/000511144","article-title":"Chemotherapy or allogeneic stem cell transplantation as salvage therapy for patients with refractory acute myeloid leukemia: a multicenter analysis","volume":"145","author":"Wang","year":"2022","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jcyt.2026.102067_bib0008","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s44313-024-00016-8","article-title":"What is new in acute myeloid leukemia classification?","volume":"59","author":"Park","year":"2024","journal-title":"Blood Res"},{"key":"10.1016\/j.jcyt.2026.102067_bib0009","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102067_bib0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.jcyt.2026.102067_bib0011","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102067_bib0012","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102067_bib0013","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1007\/s00277-023-05406-z","article-title":"Salvage hematopoietic stem cell transplantation for patients with higher leukemia burden in relapsed or refractory acute myeloid leukemia: a ten-year study","volume":"102","author":"Jiang","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jcyt.2026.102067_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/03000605221078466","article-title":"Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation: a retrospective study from a single institution","volume":"50","author":"Lin","year":"2022","journal-title":"J Int Med Res"},{"key":"10.1016\/j.jcyt.2026.102067_bib0015","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1007\/s00277-020-04283-0","article-title":"Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory\/relapsed acute myeloid leukemia not in remission status","volume":"99","author":"Lu","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jcyt.2026.102067_bib0016","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102067_bib0017","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/10428194.2017.1357173","article-title":"Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients","volume":"59","author":"Yanada","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jcyt.2026.102067_bib0018","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41375-023-02119-0","article-title":"Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission","volume":"38","author":"Yanada","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102067_bib0019","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s44313-024-00044-4","article-title":"Acute myeloid leukemia and myelodysplastic neoplasms: clinical implications of myelodysplasia-related genes mutations and TP53 aberrations","volume":"59","author":"Kim","year":"2024","journal-title":"Blood Res"},{"key":"10.1016\/j.jcyt.2026.102067_bib0020","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","article-title":"Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"23","author":"Schmid","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102067_bib0021","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2147\/CMAR.S339846","article-title":"Allogeneic stem cell transplantation with sequential melphalan-based conditioning in AML: residual morphological blast count determines the risk of relapse","volume":"14","author":"Sockel","year":"2022","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.jcyt.2026.102067_bib0022","article-title":"Decitabine-intensified modified busulfan\/cyclophosphamide conditioning regimen improves survival in acute myeloid leukemia patients undergoing related donor hematopoietic stem cell transplantation: a propensity score matched analysis","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcyt.2026.102067_bib0023","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/bmt.2014.223","article-title":"Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome","volume":"50","author":"Mo","year":"2015","journal-title":"Bone Marrow Transplant"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492600023X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492600023X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:05:19Z","timestamp":1777586719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S146532492600023X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S146532492600023X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102067","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of salvage allogeneic transplantation for relapsed or refractory AML in nonremission: insights from real-world practice","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102067"}}